Short answer
Amgen (AMGN) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $10.1B (up 9.5% year over year) with net income of $2.4B.
Q2 2026 key financials · XBRL
- Revenue
- $10.1B
- +9.5% YoY · +16.7% QoQ
- Net income
- $2.4B
- +65.9% YoY · +30.6% QoQ
- Operating margin
- 35.0%
- EPS (diluted)
- $4.37
- +65.5% YoY · +30.8% QoQ
Source: XBRL data from the Amgen (AMGN) Q2 2026 10-Q on SEC EDGAR. USD.
Amgen Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Repatha revenue $953M, up 37% YoY, driven by volume growth
- Prolia revenue $759M, down 32% YoY, worst-performing product
- Prolia volume down 20%; net selling price down 12%
- Prolia sales erosion expected to accelerate through 2026 amid biosimilar competition
Risk Factors
- New PFAS regulatory exposure, triggered by proposed EU pharmaceutical manufacturing and packaging ban
- Manufacturing and distribution disruption risk, concentrated at Louisville and Breda centers
- Regulatory approval delays from manufacturing-line quality findings extending to unrelated facilities
- Supply-chain dependence on third-party manufacturers and logistics providers, with alternatives potentially unavailable
- U.S.-focused drug-manufacturing legislation risk, including proposed Veterans Affairs purchasing restrictions on foreign APIs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amgen quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.